<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="100633">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01659359</url>
  </required_header>
  <id_info>
    <org_study_id>virtual reality glasses</org_study_id>
    <nct_id>NCT01659359</nct_id>
  </id_info>
  <brief_title>The Effect of Virtual Reality Glasses on Pain and Anxiety</brief_title>
  <official_title>Vice-presidency for Research</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Mashhad University of Medical Sciences</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Mashhad University of Medical Sciences</source>
  <oversight_info>
    <authority>Iran: Ethics Committee</authority>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      In recent studies using virtual reality has been  proposed as a non pharmacological methods
      for pain relief but until this time , its effects has not been assessed  on pain and anxiety
      during episiotomy repair. To determine  the effectiveness of virtual reality Glasses on pain
      and anxiety in Primiparity women during episiotomy repair.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>January 2011</start_date>
  <completion_date type="Actual">August 2012</completion_date>
  <primary_completion_date type="Actual">July 2012</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Virtual reality glasses decreased pain and anxiety during episiotomy</measure>
    <time_frame>up to 8 months</time_frame>
    <safety_issue>Yes</safety_issue>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">30</enrollment>
  <condition>Pain and Anxiety</condition>
  <arm_group>
    <arm_group_label>virtual reality glasses and Lidocaine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>virtual reality glasses and 5 ml Lidocaine 2%</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Lidocaine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>5 cc Lidocaine2%</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Virtual reality glasses and Lidocaine</intervention_name>
    <description>The samples were randomly allocated to use Virtual reality glasses and 5 ml Lidocaine2% for decreasing pain and anxiety in episiotomy repair.</description>
    <arm_group_label>virtual reality glasses and Lidocaine</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Lidocaine</intervention_name>
    <description>The samples were randomly allocated to use 5 ml Lidocaine2% for decreasing pain and anxiety in episiotomy repair.</description>
    <arm_group_label>Lidocaine</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Iranian

          -  low risk pregnancy

          -  Apgar â‰¥ 7

        Exclusion Criteria:

          -  vision or ear disorders

          -  History of motion sickness or headaches

          -  psychological disease or Addiction

          -  Prescribe  narcotic or sedation 4hour  prior to  delivery.
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>34 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <verification_date>August 2012</verification_date>
  <lastchanged_date>August 7, 2012</lastchanged_date>
  <firstreceived_date>August 4, 2012</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Mashhad University of Medical Sciences</investigator_affiliation>
    <investigator_full_name>Samira Ebrahimzadeh Zagami</investigator_full_name>
    <investigator_title>Principle Investigator</investigator_title>
  </responsible_party>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Anxiety Disorders</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Methamphetamine</mesh_term>
    <mesh_term>Lidocaine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
